1. Search Result
Search Result
Results for "

congenital disorder

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138802
    ML089
    1 Publications Verification

    Others Metabolic Disease
    ML089 is a potent, selective, and orally available phosphomannose isomerase (PMI) inhibitor with an IC50 of 1.3 µM. ML089 can be used for the research of congenital disorder of glycosylation Ia .
    ML089
  • HY-106203A

    SSR-125543 hydrochloride

    CFTR Metabolic Disease
    Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont hydrochloride
  • HY-124890

    Others Metabolic Disease
    Thr101 is an inhibitor (IC50=2.9 μM) of phosphomannose isomerase (PMI).PMI can compete with phosphomannose mutase 2 (PMM2) for the binding site of Man-6-P and convert mannose-6-phosphate (Man-6-P) into fructose-6-phosphate (Fru-6-P) .Thr101 only specifically inhibits PMI and not PMM2. Thr101 can be used for research of congenital disorder of glycosylation type Ia (CDG-Ia) .
    Thr101
  • HY-106203

    SSR-125543

    CFTR Metabolic Disease
    Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont
  • HY-111303

    Sirtuin Neurological Disease Inflammation/Immunology
    CHIC35, an analog of EX-527, is a potent and selective inhibitor of SIRT1 (IC50=0.124 µM). CHIC35 shows potential selective inhibition against SIRT1 over SIRT2 (IC50=2.8 µM) or SIRT3 (IC50>100 µM) . CHIC35 has anti-inflammatory effects and can be used for CHARGE syndrome research .
    CHIC35

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: